FDA EIR - Siegfried USA, LLC - December 19, 2018

An FDA surveillance inspection of Siegfried USA, LLC, an Active Pharmaceutical Ingredient (API) manufacturer, was conducted from November 30 to December 19, 2018. The inspection, focusing on Good Manufacturing Practices (GMP) and an Opioid Quality Survey, identified significant deficiencies. The main violations, documented in a 4-point FDA-483, centered on the handling of Methadone HCl. Specifically, a lot with a green tint and failing impurity specifications was not rejected or quarantined; instead, it was combined with other lots and released without adequate investigation. Related issues included failures to follow established laboratory control mechanisms, use of unvalidated test methods, and insufficient analytical data review for this product. Furthermore, the company failed to conduct adequate manufacturing investigations into drug substance discrepancies and did not perform preventative maintenance on critical manufacturing equipment at appropriate intervals. Management acknowledged the observations and planned corrective actions for some issues, such as equipment maintenance, but contested the validity of certain impurity results. The inspection highlighted a need for comprehensive improvements in process control, quality systems, and laboratory practices to ensure regulatory compliance.